According to the 2022 ESC guideline for PAH and recent articles, Prostacyclin analogs (epoprostenol, iloprost, treprostinil, beraprost, selexipag), PDE5 inhibitors (sildenafil and tadalafil), Riociguat, endothelin receptor antagonists (Ambrisentan, bosentan, and macitentan), and a novel treatment via bone morphogenetic protein receptor 2 (BMPR2), Nuclear Factor κβ, can partially treat PAH [7, 8]. Here, BMPR2 is linked to pulmonary arterial hypertension.